Kos Fund Closes at $123M, ParcelBio Launches with $13M, Korsana Emerges with $175M
Jun 14, 2026
Three biotech companies announce significant funding: Korsana Biosciences secures $175 million for neurodegenerative therapies, Kos Biotechnology Partners closes a $123 million life sciences fund, and ParcelBio launches with $13 million to advance mRNA medicines.